U.S. Markets close in 5 hrs 49 mins

Global Kidney Cancer Drugs Industry

NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Kidney Cancer Drugs market worldwide is projected to grow by US$2 Billion, driven by a compounded growth of 5.1%. Targeted Therapy, one of the segments analyzed and sized in this study, displays the potential to grow at over 5.4%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$4.6 Billion by the year 2025, Targeted Therapy will bring in healthy gains adding significant momentum to global growth.

Read the full report: https://www.reportlinker.com/p05818084/?utm_source=PRN

- Representing the developed world, the United States will maintain a 3.9% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$68.8 Million to the region's size and clout in the next 5 to 6 years. Over US$56.1 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Targeted Therapy will reach a market size of US$250.7 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 8.2% over the next couple of years and add approximately US$584.8 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include among others, Bayer AG; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Exelixis, Inc.; Novartis International AG; Pfizer, Inc.



Read the full report: https://www.reportlinker.com/p05818084/?utm_source=PRN

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Kidney Cancer Drugs Competitor Market Share Scenario Worldwide
(in %): 2019 & 2028
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: Kidney Cancer Drugs Global Market Estimates and
Forecasts in US$ Million by Region/Country: 2018-2025
Table 2: Kidney Cancer Drugs Global Retrospective Market
Scenario in US$ Million by Region/Country: 2009-2017
Table 3: Kidney Cancer Drugs Market Share Shift across Key
Geographies Worldwide: 2009 VS 2019 VS 2025
Table 4: Targeted Therapy (Therapeutic Class) World Market by
Region/Country in US$ Million: 2018 to 2025
Table 5: Targeted Therapy (Therapeutic Class) Historic Market
Analysis by Region/Country in US$ Million: 2009 to 2017
Table 6: Targeted Therapy (Therapeutic Class) Market Share
Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS
2025
Table 7: Immunotherapy (Therapeutic Class) Potential Growth
Markets Worldwide in US$ Million: 2018 to 2025
Table 8: Immunotherapy (Therapeutic Class) Historic Market
Perspective by Region/Country in US$ Million: 2009 to 2017
Table 9: Immunotherapy (Therapeutic Class) Market Sales
Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
Table 10: Angiogenesis Inhibitors (Pharmacologic Class)
Geographic Market Spread Worldwide in US$ Million: 2018 to 2025
Table 11: Angiogenesis Inhibitors (Pharmacologic Class) Region
Wise Breakdown of Global Historic Demand in US$ Million: 2009
to 2017
Table 12: Angiogenesis Inhibitors (Pharmacologic Class) Market
Share Distribution in Percentage by Region/Country: 2009 VS
2019 VS 2025
Table 13: mTOR Inhibitors (Pharmacologic Class) World Market
Estimates and Forecasts by Region/Country in US$ Million: 2018
to 2025
Table 14: mTOR Inhibitors (Pharmacologic Class) Market Historic
Review by Region/Country in US$ Million: 2009 to 2017
Table 15: mTOR Inhibitors (Pharmacologic Class) Market Share
Breakdown by Region/Country: 2009 VS 2019 VS 2025
Table 16: Monoclonal Antibodies (Pharmacologic Class) World
Market by Region/Country in US$ Million: 2018 to 2025
Table 17: Monoclonal Antibodies (Pharmacologic Class) Historic
Market Analysis by Region/Country in US$ Million: 2009 to 2017
Table 18: Monoclonal Antibodies (Pharmacologic Class) Market
Share Distribution in Percentage by Region/Country: 2009 VS
2019 VS 2025
Table 19: Cytokine Immunotherapy (IL-2) (Pharmacologic Class)
World Market Estimates and Forecasts in US$ Million by
Region/Country: 2018 to 2025
Table 20: Cytokine Immunotherapy (IL-2) (Pharmacologic Class)
Market Worldwide Historic Review by Region/Country in US$
Million: 2009 to 2017
Table 21: Cytokine Immunotherapy (IL-2) (Pharmacologic Class)
Market Percentage Share Distribution by Region/Country: 2009 VS
2019 VS 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US Kidney Cancer Drugs Market Share (in %) by Company: 2019 & 2025
Table 22: United States Kidney Cancer Drugs Market Estimates
and Projections in US$ Million by Therapeutic Class: 2018 to
2025
Table 23: Kidney Cancer Drugs Market in the United States by
Therapeutic Class: A Historic Review in US$ Million for
2009-2017
Table 24: United States Kidney Cancer Drugs Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
Table 25: United States Kidney Cancer Drugs Market Estimates
and Projections in US$ Million by Pharmacologic Class: 2018 to
2025
Table 26: Kidney Cancer Drugs Market in the United States by
Pharmacologic Class: A Historic Review in US$ Million for
2009-2017
Table 27: United States Kidney Cancer Drugs Market Share
Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
CANADA
Table 28: Canadian Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Therapeutic Class: 2018 to 2025
Table 29: Canadian Kidney Cancer Drugs Historic Market Review
by Therapeutic Class in US$ Million: 2009-2017
Table 30: Kidney Cancer Drugs Market in Canada: Percentage
Share Breakdown of Sales by Therapeutic Class for 2009, 2019,
and 2025
Table 31: Canadian Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Pharmacologic Class: 2018 to 2025
Table 32: Canadian Kidney Cancer Drugs Historic Market Review
by Pharmacologic Class in US$ Million: 2009-2017
Table 33: Kidney Cancer Drugs Market in Canada: Percentage
Share Breakdown of Sales by Pharmacologic Class for 2009, 2019,
and 2025
JAPAN
Table 34: Japanese Market for Kidney Cancer Drugs: Annual Sales
Estimates and Projections in US$ Million by Therapeutic Class
for the Period 2018-2025
Table 35: Kidney Cancer Drugs Market in Japan: Historic Sales
Analysis in US$ Million by Therapeutic Class for the Period
2009-2017
Table 36: Japanese Kidney Cancer Drugs Market Share Analysis by
Therapeutic Class: 2009 VS 2019 VS 2025
Table 37: Japanese Market for Kidney Cancer Drugs: Annual Sales
Estimates and Projections in US$ Million by Pharmacologic Class
for the Period 2018-2025
Table 38: Kidney Cancer Drugs Market in Japan: Historic Sales
Analysis in US$ Million by Pharmacologic Class for the Period
2009-2017
Table 39: Japanese Kidney Cancer Drugs Market Share Analysis by
Pharmacologic Class: 2009 VS 2019 VS 2025
CHINA
Table 40: Chinese Kidney Cancer Drugs Market Growth Prospects
in US$ Million by Therapeutic Class for the Period 2018-2025
Table 41: Kidney Cancer Drugs Historic Market Analysis in China
in US$ Million by Therapeutic Class: 2009-2017
Table 42: Chinese Kidney Cancer Drugs Market by Therapeutic
Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
Table 43: Chinese Kidney Cancer Drugs Market Growth Prospects
in US$ Million by Pharmacologic Class for the Period 2018-2025
Table 44: Kidney Cancer Drugs Historic Market Analysis in China
in US$ Million by Pharmacologic Class: 2009-2017
Table 45: Chinese Kidney Cancer Drugs Market by Pharmacologic
Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
EUROPE
Market Facts & Figures
European Kidney Cancer Drugs Market: Competitor Market Share
Scenario (in %) for 2019 & 2025
Table 46: European Kidney Cancer Drugs Market Demand Scenario
in US$ Million by Region/Country: 2018-2025
Table 47: Kidney Cancer Drugs Market in Europe: A Historic
Market Perspective in US$ Million by Region/Country for the
Period 2009-2017
Table 48: European Kidney Cancer Drugs Market Share Shift by
Region/Country: 2009 VS 2019 VS 2025
Table 49: European Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Therapeutic Class: 2018-2025
Table 50: Kidney Cancer Drugs Market in Europe in US$ Million
by Therapeutic Class: A Historic Review for the Period
2009-2017
Table 51: European Kidney Cancer Drugs Market Share Breakdown
by Therapeutic Class: 2009 VS 2019 VS 2025
Table 52: European Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Pharmacologic Class: 2018-2025
Table 53: Kidney Cancer Drugs Market in Europe in US$ Million
by Pharmacologic Class: A Historic Review for the Period
2009-2017
Table 54: European Kidney Cancer Drugs Market Share Breakdown
by Pharmacologic Class: 2009 VS 2019 VS 2025
FRANCE
Table 55: Kidney Cancer Drugs Market in France by Therapeutic
Class: Estimates and Projections in US$ Million for the Period
2018-2025
Table 56: French Kidney Cancer Drugs Historic Market Scenario
in US$ Million by Therapeutic Class: 2009-2017
Table 57: French Kidney Cancer Drugs Market Share Analysis by
Therapeutic Class: 2009 VS 2019 VS 2025
Table 58: Kidney Cancer Drugs Market in France by Pharmacologic
Class: Estimates and Projections in US$ Million for the Period
2018-2025
Table 59: French Kidney Cancer Drugs Historic Market Scenario
in US$ Million by Pharmacologic Class: 2009-2017
Table 60: French Kidney Cancer Drugs Market Share Analysis by
Pharmacologic Class: 2009 VS 2019 VS 2025
GERMANY
Table 61: Kidney Cancer Drugs Market in Germany: Recent Past,
Current and Future Analysis in US$ Million by Therapeutic Class
for the Period 2018-2025
Table 62: German Kidney Cancer Drugs Historic Market Analysis
in US$ Million by Therapeutic Class: 2009-2017
Table 63: German Kidney Cancer Drugs Market Share Breakdown by
Therapeutic Class: 2009 VS 2019 VS 2025
Table 64: Kidney Cancer Drugs Market in Germany: Recent Past,
Current and Future Analysis in US$ Million by Pharmacologic
Class for the Period 2018-2025
Table 65: German Kidney Cancer Drugs Historic Market Analysis
in US$ Million by Pharmacologic Class: 2009-2017
Table 66: German Kidney Cancer Drugs Market Share Breakdown by
Pharmacologic Class: 2009 VS 2019 VS 2025
ITALY
Table 67: Italian Kidney Cancer Drugs Market Growth Prospects
in US$ Million by Therapeutic Class for the Period 2018-2025
Table 68: Kidney Cancer Drugs Historic Market Analysis in Italy
in US$ Million by Therapeutic Class: 2009-2017
Table 69: Italian Kidney Cancer Drugs Market by Therapeutic
Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
Table 70: Italian Kidney Cancer Drugs Market Growth Prospects
in US$ Million by Pharmacologic Class for the Period 2018-2025
Table 71: Kidney Cancer Drugs Historic Market Analysis in Italy
in US$ Million by Pharmacologic Class: 2009-2017
Table 72: Italian Kidney Cancer Drugs Market by Pharmacologic
Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
UNITED KINGDOM
Table 73: United Kingdom Market for Kidney Cancer Drugs: Annual
Sales Estimates and Projections in US$ Million by Therapeutic
Class for the Period 2018-2025
Table 74: Kidney Cancer Drugs Market in the United Kingdom:
Historic Sales Analysis in US$ Million by Therapeutic Class for
the Period 2009-2017
Table 75: United Kingdom Kidney Cancer Drugs Market Share
Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
Table 76: United Kingdom Market for Kidney Cancer Drugs: Annual
Sales Estimates and Projections in US$ Million by Pharmacologic
Class for the Period 2018-2025
Table 77: Kidney Cancer Drugs Market in the United Kingdom:
Historic Sales Analysis in US$ Million by Pharmacologic Class
for the Period 2009-2017
Table 78: United Kingdom Kidney Cancer Drugs Market Share
Analysis by Pharmacologic Class: 2009 VS 2019 VS 2025
SPAIN
Table 79: Spanish Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Therapeutic Class: 2018 to 2025
Table 80: Spanish Kidney Cancer Drugs Historic Market Review by
Therapeutic Class in US$ Million: 2009-2017
Table 81: Kidney Cancer Drugs Market in Spain: Percentage Share
Breakdown of Sales by Therapeutic Class for 2009, 2019, and
2025
Table 82: Spanish Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Pharmacologic Class: 2018 to 2025
Table 83: Spanish Kidney Cancer Drugs Historic Market Review by
Pharmacologic Class in US$ Million: 2009-2017
Table 84: Kidney Cancer Drugs Market in Spain: Percentage Share
Breakdown of Sales by Pharmacologic Class for 2009, 2019, and
2025
RUSSIA
Table 85: Russian Kidney Cancer Drugs Market Estimates and
Projections in US$ Million by Therapeutic Class: 2018 to 2025
Table 86: Kidney Cancer Drugs Market in Russia by Therapeutic
Class: A Historic Review in US$ Million for 2009-2017
Table 87: Russian Kidney Cancer Drugs Market Share Breakdown by
Therapeutic Class: 2009 VS 2019 VS 2025
Table 88: Russian Kidney Cancer Drugs Market Estimates and
Projections in US$ Million by Pharmacologic Class: 2018 to 2025
Table 89: Kidney Cancer Drugs Market in Russia by Pharmacologic
Class: A Historic Review in US$ Million for 2009-2017
Table 90: Russian Kidney Cancer Drugs Market Share Breakdown by
Pharmacologic Class: 2009 VS 2019 VS 2025
REST OF EUROPE
Table 91: Rest of Europe Kidney Cancer Drugs Market Estimates
and Forecasts in US$ Million by Therapeutic Class: 2018-2025
Table 92: Kidney Cancer Drugs Market in Rest of Europe in US$
Million by Therapeutic Class: A Historic Review for the Period
2009-2017
Table 93: Rest of Europe Kidney Cancer Drugs Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
Table 94: Rest of Europe Kidney Cancer Drugs Market Estimates
and Forecasts in US$ Million by Pharmacologic Class: 2018-2025
Table 95: Kidney Cancer Drugs Market in Rest of Europe in US$
Million by Pharmacologic Class: A Historic Review for the
Period 2009-2017
Table 96: Rest of Europe Kidney Cancer Drugs Market Share
Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
ASIA-PACIFIC
Table 97: Asia-Pacific Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Region/Country: 2018-2025
Table 98: Kidney Cancer Drugs Market in Asia-Pacific: Historic
Market Analysis in US$ Million by Region/Country for the Period
2009-2017
Table 99: Asia-Pacific Kidney Cancer Drugs Market Share
Analysis by Region/Country: 2009 VS 2019 VS 2025
Table 100: Kidney Cancer Drugs Market in Asia-Pacific by
Therapeutic Class: Estimates and Projections in US$ Million for
the Period 2018-2025
Table 101: Asia-Pacific Kidney Cancer Drugs Historic Market
Scenario in US$ Million by Therapeutic Class: 2009-2017
Table 102: Asia-Pacific Kidney Cancer Drugs Market Share
Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
Table 103: Kidney Cancer Drugs Market in Asia-Pacific by
Pharmacologic Class: Estimates and Projections in US$ Million
for the Period 2018-2025
Table 104: Asia-Pacific Kidney Cancer Drugs Historic Market
Scenario in US$ Million by Pharmacologic Class: 2009-2017
Table 105: Asia-Pacific Kidney Cancer Drugs Market Share
Analysis by Pharmacologic Class: 2009 VS 2019 VS 2025
AUSTRALIA
Table 106: Kidney Cancer Drugs Market in Australia: Recent
Past, Current and Future Analysis in US$ Million by Therapeutic
Class for the Period 2018-2025
Table 107: Australian Kidney Cancer Drugs Historic Market
Analysis in US$ Million by Therapeutic Class: 2009-2017
Table 108: Australian Kidney Cancer Drugs Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
Table 109: Kidney Cancer Drugs Market in Australia: Recent
Past, Current and Future Analysis in US$ Million by
Pharmacologic Class for the Period 2018-2025
Table 110: Australian Kidney Cancer Drugs Historic Market
Analysis in US$ Million by Pharmacologic Class: 2009-2017
Table 111: Australian Kidney Cancer Drugs Market Share
Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
INDIA
Table 112: Indian Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Therapeutic Class: 2018 to 2025
Table 113: Indian Kidney Cancer Drugs Historic Market Review by
Therapeutic Class in US$ Million: 2009-2017
Table 114: Kidney Cancer Drugs Market in India: Percentage
Share Breakdown of Sales by Therapeutic Class for 2009, 2019,
and 2025
Table 115: Indian Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Pharmacologic Class: 2018 to 2025
Table 116: Indian Kidney Cancer Drugs Historic Market Review by
Pharmacologic Class in US$ Million: 2009-2017
Table 117: Kidney Cancer Drugs Market in India: Percentage
Share Breakdown of Sales by Pharmacologic Class for 2009, 2019,
and 2025
SOUTH KOREA
Table 118: Kidney Cancer Drugs Market in South Korea: Recent
Past, Current and Future Analysis in US$ Million by Therapeutic
Class for the Period 2018-2025
Table 119: South Korean Kidney Cancer Drugs Historic Market
Analysis in US$ Million by Therapeutic Class: 2009-2017
Table 120: Kidney Cancer Drugs Market Share Distribution in
South Korea by Therapeutic Class: 2009 VS 2019 VS 2025
Table 121: Kidney Cancer Drugs Market in South Korea: Recent
Past, Current and Future Analysis in US$ Million by
Pharmacologic Class for the Period 2018-2025
Table 122: South Korean Kidney Cancer Drugs Historic Market
Analysis in US$ Million by Pharmacologic Class: 2009-2017
Table 123: Kidney Cancer Drugs Market Share Distribution in
South Korea by Pharmacologic Class: 2009 VS 2019 VS 2025
REST OF ASIA-PACIFIC
Table 124: Rest of Asia-Pacific Market for Kidney Cancer Drugs:
Annual Sales Estimates and Projections in US$ Million by
Therapeutic Class for the Period 2018-2025
Table 125: Kidney Cancer Drugs Market in Rest of Asia-Pacific:
Historic Sales Analysis in US$ Million by Therapeutic Class for
the Period 2009-2017
Table 126: Rest of Asia-Pacific Kidney Cancer Drugs Market
Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
Table 127: Rest of Asia-Pacific Market for Kidney Cancer Drugs:
Annual Sales Estimates and Projections in US$ Million by
Pharmacologic Class for the Period 2018-2025
Table 128: Kidney Cancer Drugs Market in Rest of Asia-Pacific:
Historic Sales Analysis in US$ Million by Pharmacologic Class
for the Period 2009-2017
Table 129: Rest of Asia-Pacific Kidney Cancer Drugs Market
Share Analysis by Pharmacologic Class: 2009 VS 2019 VS 2025
LATIN AMERICA
Table 130: Latin American Kidney Cancer Drugs Market Trends by
Region/Country in US$ Million: 2018-2025
Table 131: Kidney Cancer Drugs Market in Latin America in US$
Million by Region/Country: A Historic Perspective for the
Period 2009-2017
Table 132: Latin American Kidney Cancer Drugs Market Percentage
Breakdown of Sales by Region/Country: 2009, 2019, and 2025
Table 133: Latin American Kidney Cancer Drugs Market Growth
Prospects in US$ Million by Therapeutic Class for the Period
2018-2025
Table 134: Kidney Cancer Drugs Historic Market Analysis in
Latin America in US$ Million by Therapeutic Class: 2009-2017
Table 135: Latin American Kidney Cancer Drugs Market by
Therapeutic Class: Percentage Breakdown of Sales for 2009,
2019, and 2025
Table 136: Latin American Kidney Cancer Drugs Market Growth
Prospects in US$ Million by Pharmacologic Class for the Period
2018-2025
Table 137: Kidney Cancer Drugs Historic Market Analysis in
Latin America in US$ Million by Pharmacologic Class: 2009-2017
Table 138: Latin American Kidney Cancer Drugs Market by
Pharmacologic Class: Percentage Breakdown of Sales for 2009,
2019, and 2025
ARGENTINA
Table 139: Argentinean Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Therapeutic Class: 2018-2025
Table 140: Kidney Cancer Drugs Market in Argentina in US$
Million by Therapeutic Class: A Historic Review for the Period
2009-2017
Table 141: Argentinean Kidney Cancer Drugs Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
Table 142: Argentinean Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Pharmacologic Class: 2018-2025
Table 143: Kidney Cancer Drugs Market in Argentina in US$
Million by Pharmacologic Class: A Historic Review for the
Period 2009-2017
Table 144: Argentinean Kidney Cancer Drugs Market Share
Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
BRAZIL
Table 145: Kidney Cancer Drugs Market in Brazil by Therapeutic
Class: Estimates and Projections in US$ Million for the Period
2018-2025
Table 146: Brazilian Kidney Cancer Drugs Historic Market
Scenario in US$ Million by Therapeutic Class: 2009-2017
Table 147: Brazilian Kidney Cancer Drugs Market Share Analysis
by Therapeutic Class: 2009 VS 2019 VS 2025
Table 148: Kidney Cancer Drugs Market in Brazil by
Pharmacologic Class: Estimates and Projections in US$ Million
for the Period 2018-2025
Table 149: Brazilian Kidney Cancer Drugs Historic Market
Scenario in US$ Million by Pharmacologic Class: 2009-2017
Table 150: Brazilian Kidney Cancer Drugs Market Share Analysis
by Pharmacologic Class: 2009 VS 2019 VS 2025
MEXICO
Table 151: Kidney Cancer Drugs Market in Mexico: Recent Past,
Current and Future Analysis in US$ Million by Therapeutic Class
for the Period 2018-2025
Table 152: Mexican Kidney Cancer Drugs Historic Market Analysis
in US$ Million by Therapeutic Class: 2009-2017
Table 153: Mexican Kidney Cancer Drugs Market Share Breakdown
by Therapeutic Class: 2009 VS 2019 VS 2025
Table 154: Kidney Cancer Drugs Market in Mexico: Recent Past,
Current and Future Analysis in US$ Million by Pharmacologic
Class for the Period 2018-2025
Table 155: Mexican Kidney Cancer Drugs Historic Market Analysis
in US$ Million by Pharmacologic Class: 2009-2017
Table 156: Mexican Kidney Cancer Drugs Market Share Breakdown
by Pharmacologic Class: 2009 VS 2019 VS 2025
REST OF LATIN AMERICA
Table 157: Rest of Latin America Kidney Cancer Drugs Market
Estimates and Projections in US$ Million by Therapeutic Class:
2018 to 2025
Table 158: Kidney Cancer Drugs Market in Rest of Latin America
by Therapeutic Class: A Historic Review in US$ Million for
2009-2017
Table 159: Rest of Latin America Kidney Cancer Drugs Market
Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
Table 160: Rest of Latin America Kidney Cancer Drugs Market
Estimates and Projections in US$ Million by Pharmacologic
Class: 2018 to 2025
Table 161: Kidney Cancer Drugs Market in Rest of Latin America
by Pharmacologic Class: A Historic Review in US$ Million for
2009-2017
Table 162: Rest of Latin America Kidney Cancer Drugs Market
Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
MIDDLE EAST
Table 163: The Middle East Kidney Cancer Drugs Market Estimates
and Forecasts in US$ Million by Region/Country: 2018-2025
Table 164: Kidney Cancer Drugs Market in the Middle East by
Region/Country in US$ Million: 2009-2017
Table 165: The Middle East Kidney Cancer Drugs Market Share
Breakdown by Region/Country: 2009, 2019, and 2025
Table 166: The Middle East Kidney Cancer Drugs Market Estimates
and Forecasts in US$ Million by Therapeutic Class: 2018 to 2025
Table 167: The Middle East Kidney Cancer Drugs Historic Market
by Therapeutic Class in US$ Million: 2009-2017
Table 168: Kidney Cancer Drugs Market in the Middle East:
Percentage Share Breakdown of Sales by Therapeutic Class for
2009, 2019, and 2025
Table 169: The Middle East Kidney Cancer Drugs Market Estimates
and Forecasts in US$ Million by Pharmacologic Class: 2018 to
2025
Table 170: The Middle East Kidney Cancer Drugs Historic Market
by Pharmacologic Class in US$ Million: 2009-2017
Table 171: Kidney Cancer Drugs Market in the Middle East:
Percentage Share Breakdown of Sales by Pharmacologic Class for
2009, 2019, and 2025
IRAN
Table 172: Iranian Market for Kidney Cancer Drugs: Annual Sales
Estimates and Projections in US$ Million by Therapeutic Class
for the Period 2018-2025
Table 173: Kidney Cancer Drugs Market in Iran: Historic Sales
Analysis in US$ Million by Therapeutic Class for the Period
2009-2017
Table 174: Iranian Kidney Cancer Drugs Market Share Analysis by
Therapeutic Class: 2009 VS 2019 VS 2025
Table 175: Iranian Market for Kidney Cancer Drugs: Annual Sales
Estimates and Projections in US$ Million by Pharmacologic Class
for the Period 2018-2025
Table 176: Kidney Cancer Drugs Market in Iran: Historic Sales
Analysis in US$ Million by Pharmacologic Class for the Period
2009-2017
Table 177: Iranian Kidney Cancer Drugs Market Share Analysis by
Pharmacologic Class: 2009 VS 2019 VS 2025
ISRAEL
Table 178: Israeli Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Therapeutic Class: 2018-2025
Table 179: Kidney Cancer Drugs Market in Israel in US$ Million
by Therapeutic Class: A Historic Review for the Period
2009-2017
Table 180: Israeli Kidney Cancer Drugs Market Share Breakdown
by Therapeutic Class: 2009 VS 2019 VS 2025
Table 181: Israeli Kidney Cancer Drugs Market Estimates and
Forecasts in US$ Million by Pharmacologic Class: 2018-2025
Table 182: Kidney Cancer Drugs Market in Israel in US$ Million
by Pharmacologic Class: A Historic Review for the Period
2009-2017
Table 183: Israeli Kidney Cancer Drugs Market Share Breakdown
by Pharmacologic Class: 2009 VS 2019 VS 2025
SAUDI ARABIA
Table 184: Saudi Arabian Kidney Cancer Drugs Market Growth
Prospects in US$ Million by Therapeutic Class for the Period
2018-2025
Table 185: Kidney Cancer Drugs Historic Market Analysis in
Saudi Arabia in US$ Million by Therapeutic Class: 2009-2017
Table 186: Saudi Arabian Kidney Cancer Drugs Market by
Therapeutic Class: Percentage Breakdown of Sales for 2009,
2019, and 2025
Table 187: Saudi Arabian Kidney Cancer Drugs Market Growth
Prospects in US$ Million by Pharmacologic Class for the Period
2018-2025
Table 188: Kidney Cancer Drugs Historic Market Analysis in
Saudi Arabia in US$ Million by Pharmacologic Class: 2009-2017
Table 189: Saudi Arabian Kidney Cancer Drugs Market by
Pharmacologic Class: Percentage Breakdown of Sales for 2009,
2019, and 2025
UNITED ARAB EMIRATES
Table 190: Kidney Cancer Drugs Market in the United Arab
Emirates: Recent Past, Current and Future Analysis in US$
Million by Therapeutic Class for the Period 2018-2025
Table 191: United Arab Emirates Kidney Cancer Drugs Historic
Market Analysis in US$ Million by Therapeutic Class: 2009-2017
Table 192: Kidney Cancer Drugs Market Share Distribution in
United Arab Emirates by Therapeutic Class: 2009 VS 2019 VS 2025
Table 193: Kidney Cancer Drugs Market in the United Arab
Emirates: Recent Past, Current and Future Analysis in US$
Million by Pharmacologic Class for the Period 2018-2025
Table 194: United Arab Emirates Kidney Cancer Drugs Historic
Market Analysis in US$ Million by Pharmacologic Class:
2009-2017
Table 195: Kidney Cancer Drugs Market Share Distribution in
United Arab Emirates by Pharmacologic Class: 2009 VS 2019 VS
2025
REST OF MIDDLE EAST
Table 196: Kidney Cancer Drugs Market in Rest of Middle East:
Recent Past, Current and Future Analysis in US$ Million by
Therapeutic Class for the Period 2018-2025
Table 197: Rest of Middle East Kidney Cancer Drugs Historic
Market Analysis in US$ Million by Therapeutic Class: 2009-2017
Table 198: Rest of Middle East Kidney Cancer Drugs Market Share
Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
Table 199: Kidney Cancer Drugs Market in Rest of Middle East:
Recent Past, Current and Future Analysis in US$ Million by
Pharmacologic Class for the Period 2018-2025
Table 200: Rest of Middle East Kidney Cancer Drugs Historic
Market Analysis in US$ Million by Pharmacologic Class:
2009-2017
Table 201: Rest of Middle East Kidney Cancer Drugs Market Share
Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
AFRICA
Table 202: African Kidney Cancer Drugs Market Estimates and
Projections in US$ Million by Therapeutic Class: 2018 to 2025
Table 203: Kidney Cancer Drugs Market in Africa by Therapeutic
Class: A Historic Review in US$ Million for 2009-2017
Table 204: African Kidney Cancer Drugs Market Share Breakdown
by Therapeutic Class: 2009 VS 2019 VS 2025
Table 205: African Kidney Cancer Drugs Market Estimates and
Projections in US$ Million by Pharmacologic Class: 2018 to 2025
Table 206: Kidney Cancer Drugs Market in Africa by
Pharmacologic Class: A Historic Review in US$ Million for
2009-2017
Table 207: African Kidney Cancer Drugs Market Share Breakdown
by Pharmacologic Class: 2009 VS 2019 VS 2025

IV. COMPETITION

BAYER AG
BRISTOL-MYERS SQUIBB COMPANY
EISAI CO.
EXELIXIS, INC.
NOVARTIS INTERNATIONAL AG
PFIZER, INC

V. CURATED RESEARCH
Read the full report: https://www.reportlinker.com/p05818084/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision

View original content:http://www.prnewswire.com/news-releases/global-kidney-cancer-drugs-industry-300937946.html